--- title: "U.S. Stock Market Midday Update: FDA Approval Can't Save Tempus AI from an 8.21% Drop? High Valuation and Negative Cash Flow Trigger Sell-off" type: "News" locale: "en" url: "https://longbridge.com/en/news/296819800.md" description: "Tempus AI fell 8.21%; Thermo Fisher Scientific fell 0.72%, with a transaction volume of USD 592 million; Agilent Technologies fell 3.69%, with a transaction volume of USD 287 million; Danaher fell 1.69%, with a transaction volume of USD 257 million; IQVIA fell 0.30%, with a market value of USD 42.6 billion" datetime: "2026-08-24T18:38:13.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296819800.md) - [en](https://longbridge.com/en/news/296819800.md) - [zh-HK](https://longbridge.com/zh-HK/news/296819800.md) generator: "portal-rs" --- # U.S. Stock Market Midday Update: FDA Approval Can't Save Tempus AI from an 8.21% Drop? High Valuation and Negative Cash Flow Trigger Sell-off **U.S. Stock Market Midday Update** Tempus AI fell 8.21%, with increased trading volume. Based on recent key news: 1. On August 24, Tempus AI received FDA 510(k) approval for its cardiovascular AI device Tempus ECG-PH. Despite the regulatory approval, the stock faced market sell-off. The stock had previously risen 9% last Friday, with some call options increasing by as much as 234%. 2. On August 24, despite the company expanding its regulated AI product portfolio, the market expressed concerns over its high valuation and negative free cash flow. The company's price-to-sales ratio is approximately 8.6 times, with a debt-to-equity ratio of 3.25, and negative free cash flow exceeding $270 million over the past twelve months. 3. On August 22, BTIG raised Tempus AI's target price from $70 to $80, maintaining a buy rating. This move was based on positive Phase III clinical trial results for the mRNA cancer therapy jointly developed by Merck and Moderna, validating Tempus AI's strategic acquisition of Personalis. The market remains concerned about high valuations and negative free cash flow. **Stocks with High Trading Volume in the Industry** Thermo Fisher Scientific fell 0.72%. Based on recent key news: 1. On August 24, MarketBeat reported that although Thermo Fisher Scientific was rated "Moderate Buy" by analysts, top analysts believe there are five stocks that are more worthy of purchase. This news may have affected investor confidence, leading to a decline in stock price. 2. On August 23, MarketBeat pointed out that Thermo Fisher Scientific was not included in the list of five stocks recommended by top analysts, despite its "Moderate Buy" rating. This information may have intensified market concerns about its future performance. 3. On August 22, MarketBeat reiterated that Thermo Fisher Scientific was not included in the analyst-recommended stock list, further impacting market confidence in the company. The market holds an optimistic view of the financial sector, with noticeable capital inflows. Agilent Technologies fell 3.69%. Based on recent key news: 1. On August 24, Dai-ichi Life Insurance established a new position in Agilent with approximately 10,759 shares, valued at about $1.43 million. Despite Morgan Stanley raising Agilent's target price to $175 and giving it an "Overweight" rating, the market reacted poorly, leading to a decline in stock price. 2. On August 24, MarketBeat noted that Agilent Technologies was not included in the list of five stocks recommended by top analysts, despite currently having a "Moderate Buy" rating among analysts, which weakened market confidence. 3. On August 24, Jefferies adjusted target prices for several other stocks but did not include Agilent Technologies, which may have led to a shift in investor attention, further impacting the stock price. The overall market performance is weak, with unstable capital flows Danaher fell 1.69%, with increased trading volume. Based on recent key news: 4. On August 21, Danaher's subsidiary Beckman Coulter won a patent lawsuit, and Cytek is required to pay $56 million in damages. This victory enhances Danaher's market competitiveness and may have a positive impact on its stock price. 5. On August 22, analysts rated Danaher as "Moderate Buy," but it was not included in the top recommended stocks list. This may lead to insufficient investor confidence, affecting stock price performance. 6. On August 23, the market remained focused on Danaher's insider trading and 13F filing updates. Although there were no significant positive news, trading activity increased. Frequent patent lawsuits in the biotechnology industry are affecting market sentiment. **Stocks ranked among the top in industry market capitalization** IQVIA fell 0.30%, with increased trading volume. Based on recent key news: 1. On August 24, MarketBeat's analysis showed that although IQVIA received a moderate buy rating from analysts, top analysts preferred five other stocks. This information may weaken investor confidence in IQVIA, thereby affecting its stock price. 2. No other significant news recently. The market is more interested in other stocks, impacting IQVIA ### Related Stocks - [TEM.US](https://longbridge.com/en/quote/TEM.US.md) - [TMO.US](https://longbridge.com/en/quote/TMO.US.md) - [A.US](https://longbridge.com/en/quote/A.US.md) - [DHR.US](https://longbridge.com/en/quote/DHR.US.md) - [IQV.US](https://longbridge.com/en/quote/IQV.US.md) ## Related News & Research - [Andrew Polovin Sells 22,148 Shares of Tempus AI (NASDAQ:TEM) Stock](https://longbridge.com/en/news/296610788.md) - [Tempus AI Diagnostics CEO Thomas Edward Schoenherr reports $188,580 Tempus AI common share sale](https://longbridge.com/en/news/297014369.md) - [Lorka AI Report Finds Higher Workplace AI Adoption Among Younger Workers](https://longbridge.com/en/news/297049938.md) - [Former Miami Mayor Francis Suarez Joins HelloGov AI as Advisor to the Board](https://longbridge.com/en/news/297064972.md) - [How to Play Wix Stock on Big Gemini AI Win](https://longbridge.com/en/news/296953485.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**